Brett Garrison

Senior Counsel

Contact Me

Services & Specializations

Admissions

District of Columbia;
New York;
US Court of Appeals, Federal Circuit

Address

1901 L Street NW, Suite 620, Washington, DC 20036

Office Tel.

619.906.5784

VCard

Overview

Brett focuses on patent litigation, in particular Hatch-Waxman/ANDA litigation, as well as broader litigation issues in the life sciences and medical device industries. His experience includes multiple Hatch-Waxman trials. He practices in Procopio’s Washington, D.C., office.

Cosmo Techs. Ltd. v. Alvogen Pine Brook LLC, No.15-cv-193-LPS (D. Del). Represented Alvogen and prevailed at trial in patent infringement litigation relating to a generic budesonide drug product (Uceris®). The Federal Circuit affirmed the judgment.
Otsuka Pharmaceutical Co., Ltd. v. Zydus Pharmaceuticals USA Inc., Nos. 14-cv-03158-JBS &14-cv-07252-JBS (D.N.J.). Represented Zydus and obtained denial of motion for temporary restraining order in patent infringement action relating to a generic aripiprazole drug product (Abilify®).
Omeros Corp. v. Par Sterile Products, LLC, No. 15-cv-773-RGA (D. Del). Represented Par in litigation involving multiple patents directed to a generic ketorolac/phenylephrine drug product (Omidria®). Secured favorable settlement after three-day bench trial.
Alcon Pharms. Ltd. v. Par Pharm. Inc., No. 15-cv-7240-PGS (D.N.J.). Represented Par in litigation involving multiple patents directed to a generic ciprofloxacin/dexamethasone drug product (Ciprodex®). Secured dismissal of case resulting in a favorable settlement for Par.

Best Lawyers® Ones to Watch, Intellectual Property Law, Life Science Practice, and Litigation-Patent, 2024-2025
Top 100 Attorney for Hatch-Waxman/ANDA Litigation, Patexia, 2024

JD, cum laude, Washington University School of Law, 2014
BA (Chemistry), New York University, 2009

Author. “3 Strategies to Manage Case Scope in ANDA Patent Litigation,” Law360, December 10, 2019.
Author. “Facilitating Competition and Innovation Isn’t Easy: FDA’s Latest Hearing On Biologics,” FDLI, September 14, 2018.
Author. “Obviousness Trends: Get the Edge,” Intellectual Property Magazine, June 2015.

American Bar Association, Intellectual Property Law Section
American Intellectual Property Law Association

Keckley, Andrea. “Fed. Circ. Won’t Pause Teva Patent Delisting For Appeal,” Law360, March 10, 2025.
Eslinger, Bonnie. “Full Fed. Circ. Won’t Take On Teva’s Orange Book Appeal,” Law360, March 3, 2025.
Davis, Ryan. “Fed. Circ. Says Teva Inhaler Patents Can’t Be In Orange Book,” Law360, December 20, 2024.
Mehta, Rani. “Behind the case: How Procopio secured life sciences PTAB win,” Managing IP, July 30, 2024.
Rodgers, Jack. “Procopio Expands IP Practice In DC With Ex-Axinn Attorney,” Law360, December 20, 2022.

Litigation, Intellectual Property

Generic Pharmaceutical Manufacturer Secures Precedential Win at U.S. Federal Circuit

Client News

Litigation, Intellectual Property

Biotech Company Succeeds in Securing Invalidation of Challenged Claims in Two More Patents Held by Competitor

Client News

Life Sciences

Procopio Named a Top Ten Firm for Hatch-Waxman/ANDA Litigation With Recognition of 3 Attorneys

Firm News

Appellate Law Services

A Record 81 Procopio Attorneys Named to 2025 Best Lawyers and Ones to Watch Lists

Press Releases

Life Sciences

Chinese Biotech Scores Big Win with U.S. Patent Office Judges

Client News

Appellate Law Services

Procopio’s 6 Locations Represented Among Our 80 Best Lawyers and Ones to Watch for 2024

Press Releases

‌

‌
‌

‌

‌
‌
‌
‌

‌
‌

‌
‌
‌

‌
‌

Representative Matters

Cosmo Techs. Ltd. v. Alvogen Pine Brook LLC, No.15-cv-193-LPS (D. Del). Represented Alvogen and prevailed at trial in patent infringement litigation relating to a generic budesonide drug product (Uceris®). The Federal Circuit affirmed the judgment.
Otsuka Pharmaceutical Co., Ltd. v. Zydus Pharmaceuticals USA Inc., Nos. 14-cv-03158-JBS &14-cv-07252-JBS (D.N.J.). Represented Zydus and obtained denial of motion for temporary restraining order in patent infringement action relating to a generic aripiprazole drug product (Abilify®).
Omeros Corp. v. Par Sterile Products, LLC, No. 15-cv-773-RGA (D. Del). Represented Par in litigation involving multiple patents directed to a generic ketorolac/phenylephrine drug product (Omidria®). Secured favorable settlement after three-day bench trial.
Alcon Pharms. Ltd. v. Par Pharm. Inc., No. 15-cv-7240-PGS (D.N.J.). Represented Par in litigation involving multiple patents directed to a generic ciprofloxacin/dexamethasone drug product (Ciprodex®). Secured dismissal of case resulting in a favorable settlement for Par.

Thought Leadership

Author. “3 Strategies to Manage Case Scope in ANDA Patent Litigation,” Law360, December 10, 2019.
Author. “Facilitating Competition and Innovation Isn’t Easy: FDA’s Latest Hearing On Biologics,” FDLI, September 14, 2018.
Author. “Obviousness Trends: Get the Edge,” Intellectual Property Magazine, June 2015.

News Coverage

Keckley, Andrea. “Fed. Circ. Won’t Pause Teva Patent Delisting For Appeal,” Law360, March 10, 2025.
Eslinger, Bonnie. “Full Fed. Circ. Won’t Take On Teva’s Orange Book Appeal,” Law360, March 3, 2025.
Davis, Ryan. “Fed. Circ. Says Teva Inhaler Patents Can’t Be In Orange Book,” Law360, December 20, 2024.
Mehta, Rani. “Behind the case: How Procopio secured life sciences PTAB win,” Managing IP, July 30, 2024.
Rodgers, Jack. “Procopio Expands IP Practice In DC With Ex-Axinn Attorney,” Law360, December 20, 2022.

Services & Specializations

Admissions

Address

Office Tel.

Overview

Representative Matters

Recognitions

Education

Thought Leadership

Community

News Coverage

Services & Specializations

Admissions

Address

Office Tel.

Overview

Representative Matters

Recognitions

Education

Thought Leadership

Community

News Coverage